Teresa Saavedra, DO
Family Medicine · Brownsville, TXNPI 1255676151
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 337 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,603, more than ten times the $180 reported in 2019. Among family medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 337 payments — averaging $23.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$1K
- AstraZeneca$885
- AbbVie$750
- Corcept Therapeutics$724
- plus $2K from 23 others
Across 84 payments — averaging $22,821 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$1.5M
- Merck$426K
What the payments were for
- Food & beverage$7,926100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 60 | $1,292 |
| Novo Nordisk | 38 | $1,218 |
| Amgen | 61 | $1,131 |
| AstraZeneca | 23 | $885 |
| AbbVie | 58 | $750 |
| Corcept Therapeutics | 20 | $724 |
| Novartis | 33 | $618 |
| Genentech USA, Inc. | 4 | $269 |
| Amarin Pharma, Inc. | 4 | $213 |
| Exact Sciences | 8 | $157 |
| Pfizer | 8 | $155 |
| Ironshore Pharmaceuticals Inc. | 1 | $105 |
| Organogenesis Inc. | 1 | $51 |
| Si-bone, Inc. | 2 | $50 |
| Merck | 1 | $33 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Merz North America, Inc. | 1 | $31 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Rhythm Pharmaceuticals, Inc. | 1 | $23 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Antares Pharma, Inc. | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Abbott | 1 | $16 |
| Redhill Biopharma Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Sumitomo Pharma America, Inc. | 1 | $15 |
| Bioventus LLC | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,934 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 23 | $41,344 |
| FarxigaDapagliflozin Propanediol | 39 | $40,672 |
| Repatha SureclickEvolocumab | 32 | $28,279 |
| MounjaroTirzepatide | 14 | $27,574 |
| Xigduo XrDapaglifloz Propaned/Metformin | 11 | $14,146 |
| Duloxetine Hcl | 35 | $2,033 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 22 | $536 |
| Tizanidine Hcl | 26 | $480 |
| Metformin Hcl ErMetformin Hcl | 38 | $353 |
| Famotidine | 15 | $322 |
| Montelukast Sodium | 26 | $307 |
| Levothyroxine Sodium | 35 | $293 |
| Losartan Potassium | 35 | $257 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 22 | $241 |
| Fluticasone Propionate | 25 | $241 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,218 | $41,34423 claims |
| AstraZenecaFarxiga | $885 | $40,67239 claims |
| Lilly USA, LLCMounjaro | $1,292 | $27,57414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Brownsville
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.